Company Profile
BioFactura, Inc.
Profile date: 2025-01-19
BioFactura, Inc.: A Detailed Company Writeup
BioFactura, Inc. is a clinical-stage biopharmaceutical company based in Frederick, Maryland, USA, operating in the biotechnology and life sciences industry. The company is fundamentally dedicated to the development and manufacturing of life-saving medicines, focusing primarily on three distinct areas: biodefense medical countermeasures, high-value biosimilars, and first-in-class novel drugs. BioFactura???s business model and operations are underpinned by its proprietary biomanufacturing platform, which is a key differentiator in the market.
Core Business and Mission
The central mission of BioFactura is to identify and fulfill unmet global biomedical and national biodefense needs through innovation in biomanufacturing. The company's work spans from the research bench to the patient, utilizing its expertise in drug and vaccine development, scale-up, and manufacturing. Its operations encompass all stages of biopharmaceutical development, including non-clinical efficacy studies, toxicology studies, process optimization, cGMP manufacturing, and clinical trials.
Key Technology: StableFast\textsuperscript{TM} Biomanufacturing Platform
A cornerstone of BioFactura???s capability is its patented StableFast\textsuperscript{TM} Biomanufacturing Platform. This proprietary system is an innovative drug and vaccine development technology designed to rapidly generate stable, high-yield cell lines. The platform is cited as the optimal choice for bringing biopharmaceuticals to market with a combination of faster timelines, lower cost, and superior-quality manufacture compared to conventional methods. The technology is leveraged across all three areas of its business???biodefense, biosimilars, and novel drugs. Specifically, the company utilizes the StableFast\textsuperscript{TM}-NS0 Biomanufacturing Platform as well as globally-proven commercial Chinese Hamster Ovary (CHO) expression systems.
Products and Pipeline
BioFactura???s product pipeline is strategically structured around areas of high global need, with a significant emphasis on national security and biopreparedness.
Biodefense Medical Countermeasures
The most prominent product in BioFactura's pipeline is its Smallpox Biodefense Therapeutic. * Description: This product is a monoclonal antibody cocktail therapeutic intended for the treatment of smallpox. It is designed to augment current medical countermeasures, guard against potential antiviral resistance, and fulfill an unmet need in the nation's biothreat preparedness. While smallpox was officially eradicated, the threat of bioterrorism or inadvertent release of the Variola Virus (VARV) necessitates stockpiling of effective treatments. * Development Status: The program is in advanced development, significantly supported by the U.S. government. BioFactura has a prime contract valued at up to $78 million from the Biomedical Advanced Research and Development Authority (BARDA), a component of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. The company has been executing on contract options to support process optimization, cGMP manufacturing of the therapeutic, and non-clinical studies (including monkeypox challenge studies in non-human primates as a surrogate for smallpox in humans). The program is advancing toward the filing of an Investigational New Drug (IND) application and a subsequent first-in-human Phase 1 clinical safety study. * Other Programs: BioFactura???s biodefense portfolio has also included past and current programs targeting other high-threat pathogens, such as Ebola.
High-Value Biosimilars (Follow-on Biologics)
BioFactura develops and manufactures high-value biosimilars???which are essentially generic versions of complex, approved biopharmaceuticals (biologics). * Example Product: A key biosimilar candidate in its pipeline is Ustekinumab (BFI-751). Ustekinumab is the biosimilar counterpart to Stelara\textsuperscript{\textregistered}, a drug used to treat autoimmune and inflammatory diseases such as psoriasis and Crohn's disease. * Status: The company has conducted clinical trials for this candidate, with pharmacokinetic profile results from a randomized Phase 1 trial having been published.
First-in-Class Novel Drugs
The company's platform is also leveraged for the development of first-in-class novel drugs. * Therapeutic Areas: BioFactura's pipeline has included novel medicines in the therapeutic area of cancer.
Services: Capitol Biologics CDMO Division
In addition to its internal product development pipeline, BioFactura offers its manufacturing and development expertise to external partners through a dedicated services division. * Capitol Biologics: BioFactura launched Capitol Biologics as its Contract Development and Manufacturing Organization (CDMO) division. * Offerings: This CDMO division leverages BioFactura's extensive biopharmaceutical industry experience in bioprocess development, scale-up, and manufacturing. Its purpose is to accelerate biologics development for clients, taking programs from concept to the clinic. The expansion of BioFactura's physical footprint, which includes increased cleanroom and laboratory space, directly supports this capability for clinical manufacturing.
In summary, BioFactura, Inc. functions as a diversified biopharmaceutical entity, utilizing its proprietary StableFast\textsuperscript{TM} platform to manufacture a portfolio of high-value biosimilars and novel therapeutics, while simultaneously serving as a key partner to the U.S. government for the development and supply of critical biodefense medical countermeasures.